Onesource Specialty Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has appointed Mr. Colin Michael Bond as an Additional Director in the Non-Executive Independent category, effective June 23, 2025, for a five-year term subject to shareholder approval. Mr. Bond is a global finance executive with 15 years of experience as CFO of three publicly listed companies across Switzerland, Germany, and the US, and has served as Board Member and Audit Committee Chairman for listed companies in Europe. He brings deep expertise in corporate finance, M&A, IPOs, corporate governance, and ESG. He holds an MBA from London Business School and is a Fellow of the Institute of Chartered Accountants in England and Wales.
The appointment of a highly experienced international finance professional to the board is likely a positive signal for shareholders, as it strengthens oversight in audit, risk, and strategic areas. Stock price impact is expected to be neutral to mildly positive, reflecting improved governance rather than any operational change.